The William B. Schwartz Division of Nephrology, located at Tufts Medical Center (Tufts MC) in Boston, has a long-standing tradition of excellence and commitment to patient care, education, research and public policy. Our division specializes in the study, diagnosis and treatment of kidney disease and high blood pressure, and can meet your needs whether you are a patient, referring physician, trainee or research partner.
Patient care
Caring for patients with kidney disease and kidney-related diagnoses is the core of what we do. Patients expect the highest in personal, compassionate and comprehensive care. Our multidisciplinary team members are experts in diagnosing and treating acute and chronic kidney diseases and high blood pressure.
We work with patients to help them choose and carry out appropriate treatment options, including medical and surgical management of causes of kidney diseases, dialysis and transplantation.
Education + training
The Division of Nephrology provides an award-winning, dynamic and unparalleled education and training experience. We offer an ACGME-accredited training program, a mentored research training program and MS or PhD degrees in clinical research.
Research
We are dedicated to improving patients' lives through clinical research by conducting relevant, state-of-the-art clinical research on kidney disease and its manifestations. We aim to eradicate individual kidney diseases where possible, identify effective treatments and reduce the burden of kidney disease on society.
Our annual research budget is over $4 million. Our division members' research interests span clinical science, translational research and patient-reported outcomes. We also conduct clinical trials for a variety of kidney diseases.
Public policy
Division members interact with many partners in government, industry and not-for-profit non-governmental organizations. We collaborate extensively with external partners and our work influences public policy about kidney disease on a large scale.
Our recent leadership and analysis of data presented at the National Kidney Foundation and Food and Drug Administration Conference on Alternative Endpoints for Clinical Trials is an example of our work to influence how health policy decisions affect patient care.